Automate Your Wheel Strategy on ZTS
With Tiblio's Option Bot, you can configure your own wheel strategy including ZTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZTS
- Rev/Share 21.6043
- Book/Share 7.6016
- PB 16.5479
- Debt/Equity 2.8499
- CurrentRatio 3.0282
- ROIC 0.2154
- MktCap 55434799263.0
- FreeCF/Share 5.2099
- PFCF 24.2816
- PE 20.6215
- Debt/Assets 0.6138
- DivYield 0.0161
- ROE 0.5823
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | ZTS | Piper Sandler | Overweight | Neutral | -- | $135 | Jan. 22, 2026 |
| Downgrade | ZTS | BofA Securities | Buy | Neutral | -- | $135 | Dec. 15, 2025 |
| Initiation | ZTS | Barclays | -- | Equal Weight | -- | $136 | Dec. 9, 2025 |
| Initiation | ZTS | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | Nov. 21, 2025 |
| Downgrade | ZTS | Leerink Partners | Outperform | Market Perform | -- | $155 | July 17, 2025 |
| Downgrade | ZTS | Stifel | Buy | Hold | -- | $160 | June 18, 2025 |
News
Why Zoetis (ZTS) is a Top Momentum Stock for the Long-Term
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why Zoetis (ZTS) is a Top Value Stock for the Long-Term
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Published: February 16, 2026 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exceptional Corporate Resilience profile and attractive sustainability opportunity set in areas like the Digital Infrastructure build-out. Oracle stands out with a strong sustainability profile, offering notable opportunities in Digital Infrastructure, Education and the development of Enhanced Skills & Innovation.
Read More
Zoetis: Why I'm Doubling Down On My Worst 2025 Pick
Published: February 16, 2026 by: Seeking Alpha
Sentiment: Positive
Zoetis is reiterated as a buy, with a 20% upside to a $159/share fair value, driven by margin expansion and a cheap valuation. ZTS delivered FY 2025 revenue of $9.5B, beating guidance, and presents expanding gross margins (83.5%) and shareholder-friendly share-count reduction via buybacks. International livestock and a robust pipeline (up to 12 blockbusters) provide secular growth tailwinds, offsetting US consumer retrenchment and competitive pressures.
Read More
Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript
Published: February 12, 2026 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (ZTS) Q4 2025 Earnings Call Transcript
Read More
Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
ZTS stock rises after Q4 earnings and revenues top estimates, as strong international growth and upbeat 2026 guidance offset U.S. softness.
Read More
Zoetis (ZTS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Zoetis (ZTS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Zoetis (ZTS) Beats Q4 Earnings and Revenue Estimates
Published: February 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.4 per share a year ago.
Read More
Zoetis Gears Up to Report Q4 Earnings: Here's What to Expect
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
ZTS is set up for Q4 earnings beat, fueled by strong international companion animal products sales, even as weaker U.S. demand weighs on results.
Read More
Curious about Zoetis (ZTS) Q4 Performance? Explore Wall Street Estimates for Key Metrics
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Zoetis (ZTS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Here's Why Zoetis (ZTS) is a Strong Momentum Stock
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
SGIOY vs. ZTS: Which Stock Is the Better Value Option?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Zoetis (ZTS).
Read More
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Read More
Here's Why Zoetis (ZTS) is a Strong Growth Stock
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Zoetis (ZTS) is a Top-Ranked Value Stock: Should You Buy?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Neutral
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (Raytheon), Capital One and Somnigroup. In addition to Insmed and BAE, we also added to L3Harris, a global aerospace and defense company.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Will Zoetis (ZTS) Beat Estimates Again in Its Next Earnings Report?
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: January 22, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera
Published: January 07, 2026 by: CNBC Television
Sentiment: Neutral
Stephanie Link, chief investment officer at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
Read More
UTHR vs. ZTS: Which Stock Is the Better Value Option?
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Drugs sector might want to consider either United Therapeutics (UTHR) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
2 Beaten-Down Stocks That Could Bounce Back in 2026
Published: December 31, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges.
Read More
4 Stocks That Declared Dividend Hikes Amid Ongoing Economic Uncertainty
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Negative
CNP, VAC, PCG and ZTS raised dividends as tech volatility and economic uncertainty push income-focused investors toward steadier stocks.
Read More
Zoetis Inc. (ZTS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published: December 04, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (ZTS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Read More
Zoetis (ZTS) Up 1.7% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock?
Read More
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.
Read More
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript
Published: December 02, 2025 by: Seeking Alpha
Sentiment: Neutral
Zoetis Inc. (ZTS) Discusses R&D Pipeline Progress and Strategic Vision in Animal Health Innovation Transcript
Read More
Zoetis: A High-Quality Compounder Now On Sale?
Published: November 14, 2025 by: Forbes
Sentiment: Neutral
Zoetis (ZTS) the world's largest animal-health company, develops and manufactures medicines, vaccines, and diagnostics for both pets and livestock. The stock has come under pressure in recent months as softer clinic traffic, uneven companion-animal demand, and a narrowed full-year outlook weighed on sentiment.
Read More
CPRX vs. ZTS: Which Stock Is the Better Value Option?
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?
Read More
Zoetis: Why I'm Still Holding The Stock But Advise Against New Positions
Published: November 07, 2025 by: Seeking Alpha
Sentiment: Negative
Zoetis faces ongoing headwinds as Librela sales disappoint, triggering a sharp post-earnings sell-off and continued stock weakness. Librela's decline, fueled by social media concerns about side effects, overshadows growth in other segments and forces lowered revenue guidance. ZTS trades at a historically low P/E of 20, with a strong product portfolio and robust pipeline, but lacks a clear near-term catalyst for recovery.
Read More
About Zoetis Inc. (ZTS)
- IPO Date 2013-02-01
- Website https://www.zoetis.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Kristin C. Peck
- Employees 13800